Trust me, trust no one.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"A careful review of the science and facts surrounding these potentially life-saving compounds is exactly what we have been fighting for, and now the State of California is showing signs of being on board." - Psycheceutical CEO, Chad Harman
— Psycheceutical (@psycheceutical) December 22, 2022
Read more: https://t.co/FZHNWfMYt9 pic.twitter.com/rDc48u0v0f
Much of the research surrounding psychedelics has centered on PTSD, depression, and other mental illnesses, but can it help smokers quit too? @NIH https://t.co/Cs3QNKEqLC pic.twitter.com/26u3vZ0ZEz
— Psycheceutical (@psycheceutical) December 22, 2022
I concur, revenues trending nicely, location becoming positive cash flow and more opportunities abound.
$FUNN
Since the COVID-19 pandemic began in 2019, the @who reports a 25% increase in #anxiety and #depression worldwide.
— Psycheceutical (@psycheceutical) December 20, 2022
More science, more treatments, more investment and more normalization around #mentalhealth are critical to relief from this global epidemic. pic.twitter.com/ixsJcKEbss
Artist and Founder of Shamanic Tonic, @EnLieux, had a recent ketamine experience where I came to him in the journey. He asked me to come sit for some photos to recreate his vision.
— Zappy Zapolin (@ZappyZapolin) December 19, 2022
Peace. Zappy pic.twitter.com/7vkHiTxn6x
Here’s OpenAI's #ChatGPT definition of a Psychedelic Concierge!
— Zappy Zapolin (@ZappyZapolin) December 12, 2022
Peace. Zappy
#psychedelicmedicine #artificalintelligence #futurism #tech pic.twitter.com/9sRhe6FISX
Hear why Strategic Advisor @Harringtonkevin believes that despite decades of scientific knowledge of the benefits of psychedelics, this medicine is becoming the future of mental health treatment. pic.twitter.com/x2w62mM7M6
— Psycheceutical (@psycheceutical) December 12, 2022
"The coming year will see a number of milestones in the emerging era of psychedelic medicines."
— Psycheceutical (@psycheceutical) December 8, 2022
Read more from @theeconomist: https://t.co/aD5IaLRebv pic.twitter.com/QyNLid9Uu3
A @CDCgov report showed more than 55 million visits to physician offices result in mental disorders as the primary diagnosis — and that was 2018. From anxiety & depression to many other severe #mentalhealth disorders, the world is experiencing a crisis that needs more solutions. pic.twitter.com/ugi7VUkPB6
— Psycheceutical (@psycheceutical) December 5, 2022
Snakes will be here for decades to come. More locations coming. The opportunities for the company are strong and so it the companies future. Looking forward to the next update.
$FUNN
Catch CEO Chad Harman and Medical Advisor Dr. Thomas Cabell on the Positive Sobriety Podcast as they chat about personal experiences with psychedelics, the state of mental health treatment today, and some of the hopeful possibilities the future holds.https://t.co/oTW3wEN6JE pic.twitter.com/R9jnJROt23
— Psycheceutical (@psycheceutical) December 2, 2022
UC Berkeley launches new program to train individuals on how to safely guide patients’ psychedelic experiences in therapeutic and research settings. #psychedelicresearchhttps://t.co/oj9gtdRZn0 pic.twitter.com/7lRffD5Efy
— Psycheceutical (@psycheceutical) December 1, 2022
Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director
Press Release | 11/29/2022
MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge technologies for the next generation of mental health treatments, today announced the addition of Dr. Aric Logsdon as the company's Scientific Director.
As an established expert in neuroscience research, Dr. Logsdon will oversee the company's drug development plans and guide the Company on providing cutting-edge biomedical research, in addition to helping further develop and manage the Company’s clinical trial pipeline.
"As a medical community, we remain largely without treatments for neuropsychiatric and neurocognitive disorders, including post-traumatic stress disorder and dementia. Psychedelics have profound effects on the human brain – which are still poorly understood,” said Dr. Aric Logsdon, Scientific Director of Psycheceutical. "I am proud to join a company with a mission to determine how psychedelics can directly impact the human brain, and I look forward to working with Psycheceutical’s other neuroscience and pharmaceutical development experts towards our goal of making these life-changing treatments more safe and accessible through Psycheceutical."
Dr. Logsdon is a biomedical scientist with specific expertise in blood-brain barrier physiology and a strong background in preclinical drug discovery for neuropsychiatric and neurocognitive disorders. He earned his Ph.D. in Pharmaceutical Sciences from West Virginia University and then completed postdoctoral training at the University of Washington. Most recently, he held a faculty appointment with the University of Washington's Department of Medicine and served as a Health Science Specialist for the U.S. Department of Veterans Affairs.
Dr. Logsdon has published over 50 peer-reviewed publications in high-impact scientific journals, including Nature Neuroscience, Nature Metabolism, Nature Aging and Alzheimer's & Dementia, and is the recipient of several prestigious honors and awards from research societies, including the Psychoneuroimmunology Research Society, the International Society for Cerebral Blood Flow and Metabolism, and the National Neurotrauma Society.
"We are excited to have Dr. Logsdon join our team of expert technologists and mental health science experts," said Chad Harman, CEO of Psycheceutical. "We look forward to the advantages of having a biomedical scientist with Dr. Logsdon's aptitude and experience in blood-brain barrier physiology to optimize the development of our brain-drug delivery technologies and help guide our drug development pipeline."
About Psycheceutical Bioscience, Inc.
Psycheceutical Bioscience, Inc. (OTC: BWVI), through its wholly-owned subsidiary Psycheceutical, Inc., is seeking to develop cutting-edge delivery technologies to support safe and effective delivery of psychedelic pharmaceutical medicines. Powered by a management and advisory team with more than 100 years combined experience in development, regulatory approval processes, and commercialization across the pharmaceutical industry, Psycheceutical is on a mission to develop, improve, and commercialize cutting-edge delivery technologies that can be used across the mental health treatment spectrum while providing safe and effective delivery of psychedelic pharmaceutical medicines. Learn more at Psycheceutical.com.
Forward-Looking Statements:
Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," “may,” “should,” “could,” "intend,” “estimate,” “plan,” "anticipate,” "expect,” “believe,” “potential” or “continue,” or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.
Contact:
Kaia Roman, VP, Strategy & Communications
kaia.roman@psycheceutical.com
Yup holiday Quarter Q2 looking good. Investors for new locations happening, winning industry
Awards. Clearly up trend. Financials
Continue to improve.
Still here still growing the company still massive interest and still private investors funding new locations.
See you at Snakes & Lattes!
$FUNN
Exactly, On a really good trend now and by the end of FY23 we could be self sustaining, we arent that far off!
Opportunity continues to abound for FUNN
$FUNN
Accumulating
$SSFT
In a major development for the future of #psychedelicmedicine, Congress announces a Congressional Psychedelics Advancing Clinical Treatments (PACT) Caucus to address the national #mentalhealth crisis through psychedelic science and research.@Benzinga: https://t.co/OtDrk0ewm0 pic.twitter.com/W4FbGEkPnd
— Psycheceutical (@psycheceutical) November 28, 2022
Its coming, change then the real show. Looking forward to it!
Locations are doing well most if not all becoming cash flow positive closing the gap to aggregate profitability this year. Opportunity abounds and new locations coming.
Clean balance sheet, Looking good for the future.
$FUNN
Did you know human usage of psychedelics dates back thousands of years? Take a deeper look into some recent scientific findings of both natural and synthetic psychedelic compounds, and how they might help
— Psycheceutical (@psycheceutical) November 22, 2022
Watch 'Can Psychedelics Cure?' on @PBS.https://t.co/uK3yOHOpNI pic.twitter.com/jx1uHpSzje
Behind the scenes from our latest company gathering, this time in Chicago, where the growing Psycheceutical team presented the latest updates from our ongoing efforts to revolutionize the next generation of mental health treatment. Stay tuned for more! pic.twitter.com/Or59umXHnH
— Psycheceutical (@psycheceutical) November 21, 2022
Nice work! Every bit counts, this is a nice accomplishment and will lend to brand strength. Future looking good!
$FUNN
Snakes & Lattes Inc. Awarded 2022’s Most Innovative Retailer of the Year at Industry Prestigious Annual TAGIE Awards, Beating Out Well-Known Industry Giants
Press Release | 11/21/2022
TORONTO, ON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Snakes & Lattes Inc. (OTC: FUNN) is excited to be the recipient of ‘2022’s Most Innovative Retailer of the Year’ at the annual prestigious Toy and Game International Excellence ‘TAGIE’ awards. Winners of the various TAGIE categories were announced at the end of the prior week’s 2022 Inventor & Innovation Conference held November 17-19th.
The annual TAGIE awards held in Chicago, IL are a significant industry showcase. There were 9 voting categories and many household names were among the winners. Snakes & Lattes was awarded the 2022 ‘Most Innovative Retailer’. Other nominees in the category included well-known names: Disney (Star Wars), Barnes and Noble, F.A.O. Schwarz, and Hasbro Pulse.
“To think of where we started as a single shop in Toronto and where we are today. For all that we have come through and toiled the past few years, I couldn’t be more humbled. The recognition we have been given here today, among so many other top leaders in the space, is truly an honor.
“This award represents everyone’s efforts over the past decade: The dedicated staff, all our incredible customers, designers and the support of the communities. To join the list of previous winners LEGO, Mastermind Toys, Exploding Kittens is such a great feeling. Thank you all for the amazing support. Very excited for what comes next for Snakes & Lattes,” said Snakes & Lattes Inc. Founder, Ben Castanie.
Previous winners of Innovative Retailers of the Year:
2021 LEGO
2020 Mastermind Toys
2019 Exploding Kittens
More information from the event can be found at:
https://www.peopleofplay.com/toy-game-innovation-awards/2022
See you at Snakes & Lattes!
About Snakes & Lattes Inc.
Snakes & Lattes Inc. currently operates 7 tabletop gaming bars and cafes: 3 located in Toronto, Ontario, Canada, 1 in Tempe, Arizona, 1 in Tucson, Arizona, 1 in Provo, Utah, and 1 in Chicago, Illinois. The company is in the process of expanding throughout North America. Snakes & Lattes Inc. was the first board game bar and cafe in North America, and is believed to be the largest in the world. Our board game cafes have the largest circulating public library of board games in North America for customers to choose from.
For more information on Snakes & Lattes Inc., please visit the website at: www.snakesandlattes.com.
For further updates from Snakes & Lattes inc., please follow us on Twitter @SnakesandLattes.
Safe Harbor Statement
This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company's OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should,", "will", "expect," "anticipate," "believe," "estimate," "confident," "intend," "plan" and other similar expressions. Our actual results, such as the Company's ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Contact:
Ben Castanie
Snakes & Lattes Inc.
Telephone: (416) 500-2911
Email: ben@snakesandlattes.com
Listen to CNN's latest podcast as Johns Hopkins University researcher Albert Garcia-Romeu joins Dr. Sanjay Gupta to talk about how psychedelics can alleviate mental suffering, and what the treatment path forward might look like.https://t.co/erXILgEJBS pic.twitter.com/js8u3rpuAF
— Psycheceutical (@psycheceutical) November 18, 2022
Sure, if thats what one wants to believe.
1000x harder to create than destroy.
$FUNN
Thats a facetious statement and doesn’t represent reality with no bearing on anything I stated.
$FUNN
TAGIE award tonight, it would be very cool if they won! Regardless it’s very cool they got nominated amongst some industry Giants. Like I said brand recognition continues to grow, snakes in Lattes will be around for a long time and just get better and better.
$FUNN
Ive been in starts ups my whole life thats why. I get it and everything that happens when bringing the company up and the myriad of challenges it faces. Do i have critical feedback? Sure, just like every company i’ve ever worked for. But i give it in a constructive manner and i use my energy to help to company as much as understand every factor and variable it deals with vs blindly tossing out accusations (which reasons usually given are simply bs 95%+ of the time) I spend my enery helping the future instead of trying to tear it down. Nothing ever going to be perfect in any company, its about what exists and what the future holds. What exists for us is a great and in demand business of board game cafes and everything that surrounds the boardgaming industry. A very loyal and growing customer base and growing revenues where some of the locations are profitable. We have millions in revenues and increasing brand strength. Opportunities abound for the company and after a couple years of pandemic hell we are truly trending in the right direction. We have momentum as a company. Yes the pps is low at the atm but with growth and opportunity and continue to trend as we are, that will drastically change for the positive. Is the stock a ‘high risk investment?’ Of course! I have ALWAYS said this, anything in the OTC is by default these are small companies. So if one leverages themselves heavily on an OTC and is upset, well thats on them not the company. I have a regular portfolio and then my otc portfolio, plenty of money to be made and done well overall. Snakes and Lattes will be around a long time, its just getting started again after a long winter. I help the company where I can and as always, look forward to the next
Update.
$FUNN
Not at all. Look at the latest Q. Revenues coming up, locations turning positive profit and closing the gap to overall profitability.
Future looks good, come through the pandemic and continues to improve and gain market brand recognition within the industry.
$FUNN
As psychedelic medicine heads toward legalization, The Future of Psychedelic Medicine: Safe, Efficient Scalability panel took a moment to focus on how the industry can scale to meet the growing demand for safe and effective mental health treatments.#WonderlandMiami pic.twitter.com/VmSNT35qOd
— Psycheceutical (@psycheceutical) November 16, 2022
It will happen, industry is building up nicely! Psycheceutical industry here to stay and on the fast rise.
Looking forward to the next update!
Thanks for the post DFLY! Yes things are looking much nicer the financials are very clean and the business is ramping up and the revenues and everything is trending in the right direction. We’ll get there yet!
Focus forward!
$FUNN
Looks like management been getting things done! All those improvements making a nice difference in the revs.
Looking forward to the next update!
$FUNN
Nice Q! Revenues solid and locations getting it done! Closing the gap to profitability, and a couple more locations coming.
Great start for the fiscal year!
$FUNN
SNAKES & LATTES INC. Is Pleased to Report a 65% Increase in YOY Q1FY23 Revenue at $1,984,097, Up From $1,203,460 for Q1FY22, With Gross Profits Up 114% From $670,985 to $1,438,243
Press Release | 11/11/2022
TORONTO, ON, Nov. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – SNAKES & LATTES INC. (OTC: FUNN) is pleased to report a 65% increase in year over year Q1FY23 revenue at $1,984,097, up from $1,203,460 for Q1FY22, with gross profits up 114% from $670,985 to $1,438,243.
We are pleased to report financials are trending in the right direction. Patronage has increased with the return of students, and have seen increases in per customer receipts.
Cash on hand at the end of the quarter was $33,440 with total assets of $3,844,156 over total liabilities of $8,990,180. The total outstanding common share count of the company is 758,849,876 as of September 30th, 2022.
Cost of goods sold remains in line with expectations, hovering around 25%.
As previously reported, we have been processing government subsidy loans incurred during the pandemic. We expect another $375,000 to be forgiven during Q2FY23.
Notable Highlights For Snakes & Lattes Locations (Q1 FY23):
‘College’ revenue up 115.52% this quarter from last year
‘Midtown’ revenue up 217.34% from last Q1 last year
‘Annex’ revenue up 147.91% from Q1 last year
‘Tempe’ is EBITDA positive for the 4th quarter in a row with $700k revenue in Q1
‘Tempe’ is on target for $3 million this FY with a net operating income over 5% even with the slower Summer period
‘Chicago’ Q1 saw a 36.84% increase over the previous quarter, this is a strong revenue improvement, trending to be EBITDA positive by Q3
‘Tucson’ saw revenues increase by 11.98% for the quarter and a particularly strong September with the return of students
Overall metrics have been improving as operational excellence initiatives and efficiencies are being actualized through a continuous flow of small improvements over time. While any singular change may not instantaneously move the needle, over time and in aggregate they collectively make a very significant impact. As we see more locations become EBITDA positive, we see the collective impact of our efforts.
Types of improvements we have implemented covering various aspects and areas of running the Snakes & Lattes locations:
Sourcing additional vendors for product stability and availability
Leveraging buying power by negotiating national contracts, discounts or fee reductions
Using technology for alerts when product purchases go above a price threshold. We use specialized software to help keep an eye on tedious pricing changes and profitability.
Utilizing online menus for easy pricing adaptability for menu adjustments
Allowing guests to place their own food and drink orders, freeing staff to focus on the customer experience and less on transactions with less labor
Pre-selling tickets for special events, allowing for better cash flow and labor forecasting
“The first quarter of the new fiscal year was a great start overall. The changes we have made over the past couple of years is paying off in markedly increased revenues per customer. As patronage continues to rise back towards pre-covid customer levels, it puts us on track for our financial goals,” said Snakes & Lattes Inc. Founder, Ben Castanie.
Ben continued, “For the first time since the pandemic, all the Canadian locations were EBITDA positive. The rise and trend in our metrics are very motivating. We do note the PPP loans and other subsidies are impacting the P&L read, but this should stop after Q2.”
Looking forward:
As we move to the busy holiday season, we are quite optimistic for a great quarter with all locations open full-time. Fiscal Year 2023 is looking to be a great growth year.
Locations have been booking holiday corporate and private events
We are receiving excellent industry recognition at the annual TAGIE awards in November
The company continues to work on other promising initiatives, which in turn are expected to continue to impact positively on the yearly aggregate growth. Details will be released on new initiatives and/or locations as milestone information becomes available.
As always, a big thank you to all our supporters and loyal customers, we continue to serve in honor to create the best possible experience for our patrons. The future of Snakes and Lattes is very bright as we continue to add on new locations, take on lucrative strategic partnerships and build our brand. Creating memorable, quality human interactive experiences keeps us going, and at all times we keep the mission of ‘Snakes and Lattes locations coast to coast’ at the forefront of our strategy.
See you at Snakes & Lattes!
About Snakes & Lattes Inc.
Snakes & Lattes Inc. currently operates 7 tabletop gaming bars and cafes: 3 located in Toronto, Ontario, Canada, 1 in Tempe, Arizona, 1 in Tucson, Arizona, 1 in Provo, Utah, and 1 in Chicago, Illinois. The company is in the process of expanding throughout North America. Snakes & Lattes Inc. was the first board game bar and cafe in North America, and is believed to be the largest in the world. Our board game cafes have the largest circulating public library of board games in North America for customers to choose from.
For more information on Snakes & Lattes Inc., please visit the website at: www.snakesandlattes.com.
For further updates from Snakes & Lattes inc., please follow us on Twitter @SnakesandLattes.
Safe Harbor Statement
This news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company's OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should,", "will", "expect," "anticipate," "believe," "estimate," "confident," "intend," "plan", “trending” and other similar expressions. Our actual results, such as the Company's ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.
Contact:
Ben Castanie
Snakes & Lattes Inc.
Telephone: (646) 992 3348
Email: investors@snakesandlattes.com
Not with packed locations bringing in millions in revenues
$FUNN
Q1 FY23 Revenues coming soon! Looking forward to seeing them, I'm optimistic it will continue to climb and be on track to close the gap to overall profitability.
I know the locations been busy since students returned so feeling good!
$FUNN
It’s not official, but it looks like psilocybin mushrooms are about to be legal in Colorado. This is going to bring incredible healing to the State! #prop122
— Zappy Zapolin (@ZappyZapolin) November 9, 2022
Peace. Zappy pic.twitter.com/DvfdeDIJdn
The @psycheceutical dream team enjoying #wonderlandmiami @MicrodoseHQ @HarringtonKevin @ZappyZapolin @kaiaroman pic.twitter.com/LNJ79oLfqw
— Psycheceutical (@psycheceutical) November 3, 2022